Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
8.72 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 59.606 | 3.686 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 6.118 | 0.754 | 0.763 | 0.455 | 0.195 | 0 | 0 |
| Gross Profit
| 53.488 | 2.932 | -0.763 | -0.455 | -0.195 | 0 | 0 |
| Gross Profit Ratio
| 0.897 | 0.795 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 110.575 | 182.435 | 145.558 | 115.308 | 36.522 | 17.94 | 3.411 |
| General & Administrative Expenses
| 0 | 122.124 | 60.971 | 21.337 | 6.61 | 1.795 | 0.695 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 184.014 | 122.124 | 60.971 | 21.337 | 6.61 | 1.795 | 0.695 |
| Other Expenses
| 11.786 | 5.821 | 0.173 | 0.967 | 1.136 | 0.48 | -0.872 |
| Operating Expenses
| 294.589 | 304.559 | 206.529 | 136.645 | 43.132 | 19.735 | 4.106 |
| Operating Income
| -241.101 | -301.627 | -206.529 | -136.645 | -43.132 | -19.735 | -4.106 |
| Operating Income Ratio
| -4.045 | -81.83 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -17.926 | -9.831 | 0.173 | 0.967 | 1.136 | 0.48 | -0.872 |
| Income Before Tax
| -259.027 | -311.458 | -206.356 | -135.678 | -41.996 | -19.255 | -4.978 |
| Income Before Tax Ratio
| -4.346 | -84.498 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 3.113 | 9.831 | -0.454 | -0.084 | 0.023 | -0.48 | -4.106 |
| Net Income
| -262.14 | -321.289 | -205.902 | -135.678 | -41.996 | -19.255 | -4.978 |
| Net Income Ratio
| -4.398 | -87.165 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -3.78 | -5.84 | -4.17 | -3.8 | -1.1 | -1.07 | -0.28 |
| EPS Diluted
| -3.78 | -5.84 | -4.17 | -3.8 | -1.1 | -1.07 | -0.28 |
| EBITDA
| -239.22 | -295.806 | -206.529 | -136.523 | -42.937 | -19.735 | -4.106 |
| EBITDA Ratio
| -4.013 | -80.251 | 0 | 0 | 0 | 0 | 0 |